Oligonucleotide therapy

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Biotechnology

Background:

• Oligonucleotide therapeutics represent a rapidly advancing field.
• Established programs are demonstrating increasing productivity.
• Recent progress builds upon foundational work from the past four years.

Purpose of the Study:

• To summarize recent advances in oligonucleotide therapeutics.
• To highlight progress in medicinal chemistry and understanding of oligonucleotide properties.
• To report on the development and clinical progression of oligonucleotide analogs.

Main Methods:

• Review of recent scientific literature and program updates.
• Analysis of advances in oligonucleotide medicinal chemistry.
• Evaluation of pharmacokinetic, pharmacodynamic, and toxicologic studies.
• Assessment of combinatorial approaches for target identification.

Main Results:

• Significant advances in oligonucleotide medicinal chemistry and pharmacodynamics.
• Improved understanding of pharmacokinetic and toxicologic properties of first-generation analogs, particularly phosphorothioates.
• One oligonucleotide, ISIS 2105, has entered clinical trials.
• Development of combinatorial methods for identifying novel oligonucleotide binders.

Conclusions:

• The field of oligonucleotide therapeutics is experiencing substantial growth and productivity.
• Key areas of advancement include drug design, property understanding, and clinical translation.
• Emerging technologies like combinatorial approaches promise further expansion of therapeutic targets.